Skip to main content
  • Jan 15, 2020

    Anti-VEGF Therapy in Patients with Neovascular AMD

    Learning Plan CME
    2.5 Self-Assessment AMA PRA Category 1 Credits™

    This learning plan is based on IRIS Registry measure IRIS45: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity. The plan reviews the impact of anti-vascular endothelial growth factor (anti-VEGF) injections in patients with wet age-related macular degeneration (AMD), including genetic predictive biomarkers of anti-VEGF treatment responses.

      Funded in part by the Retina Research Foundation